CN102378574B - 取代的偶氮蒽衍生物、药物组合物及其使用方法 - Google Patents

取代的偶氮蒽衍生物、药物组合物及其使用方法 Download PDF

Info

Publication number
CN102378574B
CN102378574B CN2010800152644A CN201080015264A CN102378574B CN 102378574 B CN102378574 B CN 102378574B CN 2010800152644 A CN2010800152644 A CN 2010800152644A CN 201080015264 A CN201080015264 A CN 201080015264A CN 102378574 B CN102378574 B CN 102378574B
Authority
CN
China
Prior art keywords
phenyl
base
compound
carbonyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010800152644A
Other languages
English (en)
Chinese (zh)
Other versions
CN102378574A (zh
Inventor
A·M·M·米贾里
C·贝梅
D·P·克里森
D·R·波里塞蒂
J·奎达
K·桑索施
M·邦德拉
M·居泽尔
R·R·亚拉冈塔
D·R·戈希姆库拉
R·C·安德鲁斯
S·T·戴维斯
T·S·约库姆
J·L·R·弗里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Publication of CN102378574A publication Critical patent/CN102378574A/zh
Application granted granted Critical
Publication of CN102378574B publication Critical patent/CN102378574B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800152644A 2009-03-30 2010-03-30 取代的偶氮蒽衍生物、药物组合物及其使用方法 Active CN102378574B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US61/164,523 2009-03-30
US30934810P 2010-03-01 2010-03-01
US61/309,348 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
CN102378574A CN102378574A (zh) 2012-03-14
CN102378574B true CN102378574B (zh) 2013-11-20

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800152644A Active CN102378574B (zh) 2009-03-30 2010-03-30 取代的偶氮蒽衍生物、药物组合物及其使用方法

Country Status (17)

Country Link
US (3) US8383644B2 (enExample)
EP (1) EP2413693B1 (enExample)
JP (1) JP5755217B2 (enExample)
KR (1) KR101732978B1 (enExample)
CN (1) CN102378574B (enExample)
AU (1) AU2010232750B2 (enExample)
BR (1) BRPI1013579A2 (enExample)
CA (1) CA2757084C (enExample)
DK (1) DK2413693T3 (enExample)
EA (1) EA023430B1 (enExample)
ES (1) ES2553645T3 (enExample)
IL (1) IL214822A (enExample)
MA (1) MA33219B1 (enExample)
MX (1) MX2011010347A (enExample)
SG (1) SG174205A1 (enExample)
TN (1) TN2011000437A1 (enExample)
WO (1) WO2010114824A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
TWI918593B (zh) 2018-05-08 2026-03-21 美商Ｖｔｖ治療有限責任公司 Glp1r激動劑的治療用途
US12709614B2 (en) 2023-09-14 2026-08-18 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
WO2013059215A1 (en) 2011-10-17 2013-04-25 Biotheryx, Inc. Substituted biaryl alkyl amides
SG10201704716XA (en) 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
MX2022008938A (es) * 2020-01-20 2022-10-18 Crescenta Biosciences Nuevos compuestos moduladores del metabolismo celular y usos de los mismos.
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021238964A1 (zh) 2020-05-28 2021-12-02 杭州中美华东制药有限公司 一种glp-1受体激动剂游离碱的制备方法
WO2021242806A1 (en) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermediates and methods for preparing a glp-1 receptor agonist
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN115667219B (zh) * 2020-05-28 2024-11-15 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
WO2021238962A1 (zh) 2020-05-28 2021-12-02 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
JP7812052B2 (ja) 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
JP7214053B2 (ja) * 2020-10-08 2023-01-27 イーライ リリー アンド カンパニー 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物
CN116348464B (zh) 2020-10-12 2026-06-16 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116940561B (zh) 2021-03-22 2026-08-11 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
EP4317145A4 (en) 2021-03-24 2025-03-12 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
WO2022262143A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN117897387B (zh) * 2021-09-03 2026-06-19 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
KR20240056719A (ko) 2021-09-08 2024-04-30 시오노기 앤드 컴파니, 리미티드 항비만 작용이 관여하는 질환의 예방 및 치료용 의약
US20250332157A1 (en) * 2021-09-28 2025-10-30 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Solid composition of glp-1 receptor agonist
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
AU2025207498A1 (en) 2024-01-09 2026-07-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Glp-1r agonist pharmaceutical composition and use thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87100658A (zh) * 1986-02-11 1987-09-09 武田药品工业株式会社 1，4-苯并嗪类衍生物，它们的制备和应用
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
CN1658871A (zh) * 2001-12-21 2005-08-24 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
US20060178515A1 (en) * 2003-03-26 2006-08-10 Hamed Aissaoui Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
JP2004529132A (ja) * 2001-03-27 2004-09-24 アクテリオン　ファマシューティカルズ　リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
EP1438310B1 (en) * 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US8466296B2 (en) * 2007-03-26 2013-06-18 Ligand Pharmaceuticals Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87100658A (zh) * 1986-02-11 1987-09-09 武田药品工业株式会社 1，4-苯并嗪类衍生物，它们的制备和应用
CN1658871A (zh) * 2001-12-21 2005-08-24 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
US20060178515A1 (en) * 2003-03-26 2006-08-10 Hamed Aissaoui Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI918593B (zh) 2018-05-08 2026-03-21 美商Ｖｔｖ治療有限責任公司 Glp1r激動劑的治療用途
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12703700B2 (en) 2023-09-14 2026-08-11 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12709614B2 (en) 2023-09-14 2026-08-18 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Also Published As

Publication number Publication date
KR20120006506A (ko) 2012-01-18
US20130096150A1 (en) 2013-04-18
IL214822A0 (en) 2011-11-30
JP2012522060A (ja) 2012-09-20
US8383644B2 (en) 2013-02-26
HK1164050A1 (en) 2012-09-21
US20150148539A1 (en) 2015-05-28
SG174205A1 (en) 2011-10-28
MX2011010347A (es) 2011-11-29
TN2011000437A1 (en) 2013-03-27
BRPI1013579A2 (pt) 2020-11-03
DK2413693T3 (en) 2015-11-16
CA2757084C (en) 2017-08-29
JP5755217B2 (ja) 2015-07-29
IL214822A (en) 2016-08-31
KR101732978B1 (ko) 2017-05-08
EP2413693A1 (en) 2012-02-08
AU2010232750A1 (en) 2011-09-08
CA2757084A1 (en) 2010-10-07
EP2413693B1 (en) 2015-09-09
AU2010232750B2 (en) 2015-10-29
EA201171197A1 (ru) 2012-04-30
ES2553645T3 (es) 2015-12-10
US20110160198A1 (en) 2011-06-30
WO2010114824A8 (en) 2011-10-06
EP2413693A4 (en) 2012-08-22
EA201171197A8 (ru) 2014-10-30
CN102378574A (zh) 2012-03-14
WO2010114824A1 (en) 2010-10-07
MA33219B1 (fr) 2012-04-02
US9175003B2 (en) 2015-11-03
US8987295B2 (en) 2015-03-24
EA023430B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
JP5755217B2 (ja) 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
CN115698003B (zh) 杂环glp-1激动剂
AU2009221722B2 (en) Oxadiazoanthracene compounds for the treatment of diabetes
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP2023515404A (ja) ヘテロ環ｇｌｐ－１アゴニスト
CN115667250A (zh) 杂环glp-1激动剂
NL2000581C2 (nl) Aangecondenseerde fenylamidoheterocyclische verbindingen.
JP4256150B2 (ja) エンドテリン介在障害治療用のスルホンアミド類
CN106983751A (zh) 二环取代尿嘧啶及其用途
EP3617195A1 (en) Novel tetrahydronaphthyl urea derivatives
WO2024140850A1 (zh) 一种蛋白酪氨酸激酶抑制剂及其医药用途
CN116457346A (zh) 作为新型二酰基甘油酯o-酰基转移酶2抑制剂的吲哚酮衍生物的制备
CA2728156A1 (en) Pyridone compounds
CA3200710A1 (en) Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
HK1164050B (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2026086876A1 (zh) 作为glp-1r激动剂的化合物
HK40085148A (en) Heterocyclic glp-1 agonists
CN114478482A (zh) 一种含稠环的化合物、其应用及含其的组合物
HK1148435B (en) Oxadiazoanthracene compounds for the treatment of diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1164050

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: TRANSFORMATION TECHNOLOGY PHARMA, LLC

Free format text: FORMER OWNER: TRANSTECH PHARMA INC.

Effective date: 20140328

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140328

Address after: North Carolina

Patentee after: TRANSTECH PHARMA, Inc.

Address before: North Carolina

Patentee before: Transtech Pharma, Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1164050

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: VTV THERAPEUTICS LLC

Free format text: FORMER NAME: TRANSFORMATION TECHNOLOGY PHARMA, LLC

CP01 Change in the name or title of a patent holder

Address after: North Carolina

Patentee after: vTv Therapeutics LLC

Address before: North Carolina

Patentee before: TRANSTECH PHARMA, Inc.

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: North Carolina

Patentee after: VTVX Holdings I LLC

Address before: North Carolina

Patentee before: VTV THERAPEUTICS LLC

TR01 Transfer of patent right

Effective date of registration: 20151127

Address after: North Carolina

Patentee after: vTv Therapeutics LLC

Address before: North Carolina

Patentee before: VTVX Holdings I LLC

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20120314

Assignee: HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL Co.,Ltd.

Assignor: VTV THERAPEUTICS LLC

Contract record no.: 2018990000060

Denomination of invention: Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Granted publication date: 20131120

License type: Exclusive License

Record date: 20180313

EE01 Entry into force of recordation of patent licensing contract